menu
    • menu
    [{"orgOrder":0,"company":"Exousia Pro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Exousia Pro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exousia Pro \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Exousia Pro \/ Undisclosed"},{"orgOrder":0,"company":"Exousia Pro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Exousia Pro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exousia Pro \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Exousia Pro \/ Undisclosed"},{"orgOrder":0,"company":"Exousia Pro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Maxasome","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Exousia Pro","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Drops","sponsorNew":"Exousia Pro \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Exousia Pro \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Exousia Pro

    Menu

    Exousia Pro

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maxasome,Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exousia Pro, Inc. Revolutionizes Nutraceuticals with Launch of Maxasome(TM)

                            Details : Maxasome, a dietary supplement, shows promising results in treating Aging.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 05, 2025

                            Lead Product(s) : Maxasome,Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exousia Pro Receives Orphan Drug Designation from FDA

                            Details : An undisclosed miscellaneous product is showing promising results in treating glioblastoma multiforme (GBM).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 28, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Exousia Pro

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exousia Pro Finishes Glioblastoma Preclinical Trial Early for Orphan Filing

                            Details : Exousia Pro completed a preclinical glioblastoma trial early, showing their exosome therapy combined with temozolomide boosts cancer stem cell death, supporting their orphan drug application.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Undisclosed,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.